A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

CorVent Medical Closes $4.5M Seed Financing

To Commercialize The First Single-Use, Critical Care Ventilator

CorVent Medical, a Coridea portfolio company, announced today the closing of a $4.5M seed financing round to support the commercialization of the first single-use, critical care ventilator that will enable rapid and affordable deployment with superior infection control.

CorVent Medical notes the financing round is led by the prominent European life sciences venture capital firm Sofinnova Partners with participation from Redmile Group, Exor Seeds, Genesis Medtech Group, The Deerfield Foundation, The Pagliuca Family Office, and Accel Founder Jim Swartz. Funds will be used to finalize regulatory filings under the U.S. Food and Drug Administration’s Emergency Use Authorization (EUA) Act, to upon approval launch the CorVentâ„¢ Single-Use Ventilator, and to support future development of next-generation lifesaving devices for respiratory insufficiency.

“The COVID-19 pandemic has highlighted a significant need for emergency-use ventilators that can be rapidly deployed to enable on-demand, critical care ventilation,” stated Antoine Papiernik, Managing Partner at Sofinnova Partners. “CorVent has created an elegant yet simple, single-use solution for emergency preparedness that can be stored for long periods of time without the expense and delay of complicated service contracts. We are proud to partner with this proven team to bring a much-needed solution to market.”

The CorVentâ„¢ Single-Use Ventilator is designed to meet each patient’s respiratory needs in an easy plug and play set-up with built-in safeguards. The single-patient design provides superior infection control with integrated filters to protect healthcare providers, staff and patients. Delivering critical care ventilation at a moment’s notice, the CorVentâ„¢ Single-Use Ventilator complements existing products during hospital shortages or in underserved markets.

“Our product is unique in that it is the only single-use, critical care ventilator that extends capacity when needed most,” commented Mark Gelfand, CEO of CorVent. “Whether it is in response to a pandemic or to address an underserved market, our single-use ventilator enables hospitals, states, and countries to cost-effectively and efficiently address respiratory insufficiency so healthcare providers can immediately focus on critical patient needs.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy